» Articles » PMID: 35165289

Regulation of P53 Signaling in Breast Cancer by the E3 Ubiquitin Ligase RNF187

Overview
Journal Cell Death Dis
Date 2022 Feb 15
PMID 35165289
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor suppressor P53 plays critical role in preventing cancer. P53 is rarely mutated and remains functional in luminal-type breast cancer(1). According to current knowledge, wild-type P53 function is tightly controlled by posttranslational modifications, such as ubiquitination. Several ubiquitin ligases have been shown to regulate P53 ubiquitination and protein stability. Here, we report that RNF187, a RING family ubiquitin ligase, facilitates breast cancer growth and inhibits apoptosis by modulating P53 signaling. RNF187 expression was elevated in breast cancer and correlated with breast cancer survival only in the P53 wild-type groups. Bioinformatic analysis showed that the expression of RNF187 was negatively correlated with the expression of P53 target genes, such as IGFBP3 and FAS, in breast cancer. RNF187 depletion inhibited breast cancer growth and facilitated cell death. RNA sequencing analysis indicated that RNF187 could be an important modulator of P53 signaling. Further experiments showed that RNF187 interacts with P53 and promotes its degradation by facilitating its polyubiquitination in breast cancer cells. Interestingly, the in vitro ubiquitin assay showed that RNF187 can directly ubiquitinate P53 in a manner independent of MDM2. These findings reveal a novel direct P53 regulator and a potential therapeutic target for breast cancer.

Citing Articles

A comprehensive pan-cancer analysis of RNF187 in human tumors.

Zhang X, Zhang X, Liu T, Sha K Discov Oncol. 2025; 16(1):37.

PMID: 39804497 PMC: 11730043. DOI: 10.1007/s12672-025-01795-x.


Combinatorial effects of cannabinoid receptor 1 and 2 agonists on characteristics and proteomic alteration in MDA-MB-231 breast cancer cells.

Chutoe C, Inson I, Krobthong S, Phueakphud N, Khunluck T, Wongtrakoongate P PLoS One. 2024; 19(11):e0312851.

PMID: 39527598 PMC: 11554208. DOI: 10.1371/journal.pone.0312851.


Exploring the Role of Unconventional Post-Translational Modifications in Cancer Diagnostics and Therapy.

Sharma S, Sarkar O, Ghosh R Curr Protein Pept Sci. 2024; 25(10):780-796.

PMID: 38910429 DOI: 10.2174/0113892037274615240528113148.


G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis.

Parija M, Adhya A, Mishra S Oncotarget. 2023; 14:466-480.

PMID: 37204251 PMC: 10197958. DOI: 10.18632/oncotarget.28433.


F-Box Protein 43, Stabilized by N6-Methyladenosine Methylation, Enhances Hepatocellular Carcinoma Cell Growth and Invasion via Promoting p53 Degradation in a Ubiquitin Conjugating Enzyme E2 C-Dependent Manner.

Zhou H, Zeng C, Liu J, Luo H, Huang W Cancers (Basel). 2023; 15(3).

PMID: 36765911 PMC: 9913344. DOI: 10.3390/cancers15030957.


References
1.
Ponde N, Zardavas D, Piccart M . Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 2018; 16(1):27-44. DOI: 10.1038/s41571-018-0089-9. View

2.
Oren M, Bienz B, Lavie V, Hazum S, Givol D . A single gene and a pseudogene for the cellular tumour antigen p53. Nature. 1983; 306(5943):594-7. DOI: 10.1038/306594a0. View

3.
Wetzel C, Berberich S . p53 binds to cisplatin-damaged DNA. Biochim Biophys Acta. 2001; 1517(3):392-7. DOI: 10.1016/s0167-4781(00)00305-5. View

4.
Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V . p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol. 2007; 18(6):997-1003. DOI: 10.1093/annonc/mdm075. View

5.
Bertheau P, Turpin E, Rickman D, Espie M, De Reynies A, Feugeas J . Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. 2007; 4(3):e90. PMC: 1831731. DOI: 10.1371/journal.pmed.0040090. View